by | Jun 20, 2024 | Publications
Cornea. 2024 Jun 18. doi: 10.1097/ICO.0000000000003596. Online ahead of print. ABSTRACT PURPOSE: The treatment of patients with relapsed/refractory multiple myeloma (RRMM) with the antibody-drug conjugate belantamab mafodotin is affected by ocular adverse effects,...
by | Jun 20, 2024 | Publications
Oncology (Williston Park). 2024 Jun 10;38(6):239-241. doi: 10.46883/2024.25921023. ABSTRACT The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials. PMID:38899981 | DOI:10.46883/2024.25921023
by | Jun 20, 2024 | Publications
Clin Cancer Res. 2024 Jun 20. doi: 10.1158/1078-0432.CCR-24-0545. Online ahead of print. ABSTRACT PURPOSE: In multiple myeloma (MM), therapy-induced clonal evolution is associated with treatment resistance and is one of the most important hindrances toward a cure for...
by | Jun 20, 2024 | Publications
Ann Hematol. 2024 Jun 20. doi: 10.1007/s00277-024-05843-4. Online ahead of print. ABSTRACT Although substantial quantities of potent therapies for multiple myeloma (MM) have been established, MM remains an incurable disease. In recent years, our understanding of the...
by | Jun 20, 2024 | Publications
Pharmacoecon Open. 2024 Jun 20. doi: 10.1007/s41669-024-00503-9. Online ahead of print. ABSTRACT BACKGROUND AND OBJECTIVE: This study aimed to assess the cost-effectiveness of two regimens regarded as the standard of care for the treatment of newly diagnosed,...
